Rhythm Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results; IMCIVREE Revenue $57.3M in Q4

RHYTHM PHARMACEUTICALS, INC.

2025-FY EPS reported -$3.11 revenue$189,757,000

Q4 2025 IMCIVREE revenue $57.3M, up 12% sequentially; full year revenue $194.8M vs $130.1M in 2024.
FDA PDUFA date March 20, 2026 for setmelanotide in acquired hypothalamic obesity.
Positive end-of-Phase-2 meeting with FDA for bivamelagon in acquired HO; Phase 3 trial to start by end of 2026.
Cash and investments $388.9M at Dec 31, 2025; net loss $48.8M in Q4 2025 vs $44.6M in Q4 2024.
Topline data expected March 2026 from Phase 3 EMANATE trial and Japanese cohort in acquired HO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.